Calidi Biotherapeutics Inc. Cash Flow Conversion Efficiency
Calidi Biotherapeutics Inc. cash flow conversion efficiency. Based on the latest financial reports, Calidi Biotherapeutics Inc. (CLDI) has a cash flow conversion efficiency ratio of -1.342x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.04 Million) by net assets ($3.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Calidi Biotherapeutics Inc. (2020–2025)
Cash flow conversion efficiency of Calidi Biotherapeutics Inc. from 2020 to 2025. This chart illustrates how Calidi Biotherapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View CLDI live share price for real-time trading data and today's change.
Calidi Biotherapeutics Inc. Cash Flow Conversion Ratio Explained
Calidi Biotherapeutics Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Calidi Biotherapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Calidi Biotherapeutics Inc. ranked by their cash flow conversion efficiency. Also see CLDI market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pomvom
TA:PMVM
|
0.429x |
|
Omega Therapeutics Inc
NASDAQ:OMGA
|
-1.214x |
|
SQX Resources Ltd
AU:SQX
|
0.000x |
|
Smooth Rock Ventures Corp
V:SMRV
|
-0.028x |
|
Central Asia Metals Plc
LSE:CAML
|
0.174x |
|
Lavide Holding NV
AS:LVIDE
|
-0.350x |
|
Evogene
TA:EVGN
|
-0.220x |
|
MMC Sanayi ve Ticari Yatirimlar AS
IS:MMCAS
|
0.001x |
Annual Cash Flow Conversion Efficiency for Calidi Biotherapeutics Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Calidi Biotherapeutics Inc. from 2020 to 2025. Review Calidi Biotherapeutics Inc. leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.76 Million | $-21.29 Million | -5.665x | +43.39% |
| 2024-12-31 | $1.97 Million | $-19.69 Million | -10.007x | -405.41% |
| 2023-12-31 | $-8.23 Million | $-26.98 Million | 3.277x | +1150.74% |
| 2022-12-31 | $-50.44 Million | $-13.21 Million | 0.262x | -23.80% |
| 2021-12-31 | $-22.61 Million | $-7.77 Million | 0.344x | +60.15% |
| 2020-12-31 | $-22.48 Million | $-4.83 Million | 0.215x | -- |
About Calidi Biotherapeutics Inc.
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast ca… Read more